 RedHill Biopharma Ltd. NASDAQ:RDHL has announced the receipt of two Notices of Allowance from the US Patent and Trademark Office USPTO covering opaganib and RHB-107 upamostat, as methods for the treatment of coronavirus COVID-19 caused by the SARS-CoV-2 virus. 